Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Ga-68 Dolacga PET Scan in Patients With Hepatocellular Carcinoma Under Radiofrequency Ablation

NCT06792097 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06792097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Ga-68 Dolacga PET Scan in Patients With Hepatocellular Carcinoma Under Radiofrequency Ablation
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
February 1, 2025
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

computed tomography, deep learning, hepatocellular carcinoma (hcc), pet scan, radiofrequency ablation